Market research
SRNE Sorrento Therape
OTCQB USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 441K
- P/E ratio
- Not available
- Analyst target
- 13
- Dividend yield
- Not available
- Beta
- 0.12
Profile
Company facts
- Exchange
- OTCQB
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US83587F2020
- Market cap
- 441K
- P/E ratio
- Not available
- Analyst target
- 13
- Dividend yield
- Not available
- Beta
- 0.12
About
About Sorrento Therape
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SRNE discussion.
5 years, 4 months ago
Sorrento Therapeutics, Inc is currently in a long term uptrend where the price is trading 7.2% above its 200 day moving average.
From a valuation standpoint, the stock is 96.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 46.0.
Sorrento Therapeutics, Inc's total revenue sank by 11.7% to $12M since the same quarter in the previous year.
Its net income has dropped by 13.8% to $-72M since the same quarter in the previous year.
Finally, its free cash flow fell by 38.0% to $-52M since the same quarter in the previous year.
Based on the above factors, Sorrento Therapeutics, Inc gets an overall score of 2/5.